Composition containing a bio-based surfactant and manganese

Abstract

The present invention relates to a composition comprising a bio-based surfactant and manganese. The present invention further relates to a method for stabilizing the color of a composition comprising a bio-based surfactant, and to the use of manganese for stabilizing the color of a composition comprising a bio-based surfactant.

Description

[Technical Field]

[0001] The present invention relates to a composition comprising a bio-based surfactant and manganese. The present invention further relates to a method for stabilizing the color of a composition comprising a bio-based surfactant, and to the use of manganese for stabilizing the color of a composition comprising a bio-based surfactant.

[0002] Background technology Surfactants are used in many different compositions and applications. Due to the need for increased sustainability, bio-based surfactants are increasingly replacing typical surfactants, which are often based on petrochemicals or non-renewable raw materials.

[0003] Bio-based surfactants, which are glycolipids produced by fermentation, are difficult to purify and / or concentrate in a colorless state. Furthermore, bio-based surfactants have the disadvantage of exhibiting color instability, tending to darken and / or turn brown during storage.

[0004] While this color instability may not be a major issue in technical applications such as oilfield or fracking, it could hinder the evaluation of bio-based surfactants in fields such as cosmetics or home care.

[0005] Therefore, an object of the present invention is to provide a bio-based surfactant composition with stable color.

[0006] Description of the Invention Surprisingly, it was found that the addition of a small amount of manganese could stabilize compositions containing bio-based surfactants in terms of color.

[0007] Therefore, the present invention provides a composition comprising a biological surfactant and manganese in a specific amount.

[0008] The present invention further provides a method for stabilizing the color of a composition containing a biosurfactant, and the use of manganese for stabilizing the color of a composition containing a biosurfactant.

[0009] One advantage of the present invention is that the composition according to the present invention has a positive odor profile.

[0010] Another advantage of the present invention is that the composition according to the present invention has improved color stability. The discoloration reaction can be attributed to the Maillard reaction, which is a chemical reaction between proteins or amino acids and sugars. Both reaction partners of proteins and sugars are usually contained in small amounts in biosurfactants produced by fermentation, such as rhamnolipids, sophorolipids or rubiwettin. Even at these low concentrations, they are sufficient for the color to change from light to dark.

[0011] A further advantage is that the composition according to the present invention has improved surface cleaning properties.

[0012] Another advantage is that the composition according to the present invention has excellent foaming properties.

[0013] A further advantage of the composition according to the present invention is that the irritation to human skin is reduced.

[0014] Another advantage of the composition according to the present invention is its low irritation and good physiological compatibility, which are characterized by high values especially in the red blood cell (RBC) test.

[0015] A further advantage of the composition according to the present invention is its good feel during and after washing.

[0016] Another advantage of the composition according to the present invention is that it leaves a smooth and soft feel on the skin after washing. <00E0091>

[0017] Another advantage of the composition according to the present invention is its remarkable microbial stability.

[0018] Another advantage is that the composition according to the invention has an improved ability to dissolve fats and oils.

[0019] Another advantage is that the composition according to the invention provides better chemical stability of the raw materials, which increases the shelf life.

[0020] Another advantage is that the composition according to the invention results in fewer side reactions and higher formulation purity.

[0021] Another advantage of the present invention is that the composition according to the invention exhibits particularly good emulsifying and dispersing properties.

[0022] One advantage of the present invention is that the composition of the present invention has very good cleaning performance, particularly in removing oil stains from fabrics.

[0023] Another advantage of the present invention is that the composition of the present invention can be very easily rinsed off from the cleaned surface or fibers.

[0024] A further advantage is that the composition of the present invention supports enzyme stability with respect to storage.

[0025] One advantage of the present invention is that the composition of the present invention is homogeneous even at low pH values.

[0026] Another advantage of the present invention is that the composition of the present invention is more easily diluted, particularly in an aqueous medium.

[0027] Another advantage of the present invention is that the composition of the present invention is readily miscible with other surfactants.

[0028] A further advantage of the present invention is that the composition of the present invention can be more easily incorporated into cosmetic formulations.

[0029] Another advantage of the present invention is that the composition of the present invention enables the formulation of concentrated surfactant formulations even at very low pH.

[0030] Another advantage of the present invention is that, due to its high concentration and achievable low pH value, the composition of the present invention has a reduced tendency to foam, making it easier to transport and deliver.

[0031] Another advantage of the present invention is that the composition of the present invention allows for the easy incorporation of hydrophobic components such as oils.

[0032] Another advantage of the present invention is that the compositions of the present invention have high storage stability.

[0033] A further advantage of the present invention is that the compositions of the present invention cause less contamination during manufacturing and transport in pipelines, and also allow for easier cleaning.

[0034] Another advantage of the present invention is that the compositions of the present invention have a very low freezing point, which means that the compositions remain processable even at low temperatures.

[0035] Another advantage of the present invention is that the compositions of the present invention, in particular cosmetic formulations or cleaning formulations, maintain color stability.

[0036] Another advantage of the present invention is that the compositions of the present invention, in particular cosmetic formulations or cleaning formulations, have lower color intensity.

[0037] The present invention A) At least one biological surfactant in an amount of 0.5% to 90% by weight, preferably 3.0% to 85% by weight, more preferably 15% to 80% by weight, more preferably 25% to 75% by weight, and most preferably 40% to 70% by weight, B) Manganese ions in a concentration of 0.01 ppm to 500 ppm, preferably 0.1 ppm to 200 ppm, more preferably 1.0 ppm to 50 ppm, and most preferably 2.0 ppm to 19 ppm. A composition comprising, This includes compositions in which the weight percentages and parts per million are relative to the whole composition.

[0038] In the context of this invention, "biological surfactant" is understood to mean all glycolipids produced by fermentation. The term "biological surfactant" also includes glycolipids that have been chemically or enzymatically modified after fermentation, as long as the glycolipid structure remains intact.

[0039] The raw materials for producing bio-based surfactants that can be used are carbohydrates, especially sugars, such as glucose and / or lipophilic carbon sources, such as fats, oils, partial glycerides, fatty acids, fatty alcohols, and long-chain saturated or unsaturated hydrocarbons.

[0040] In the context of this invention, the term "surfactant" is understood to mean an organic substance having surfactant properties that, at a concentration of 0.5% by weight based on 20°C and the entire composition, has the ability to reduce the surface tension of water to less than 45 mN / m. The surface tension is determined by the Dunuiring method at 20°C.

[0041] When averages are listed below, unless otherwise specified, they refer to the average of numerical averages.

[0042] Unless otherwise specified, percentages are given in weight percentages.

[0043] Unless otherwise specified, parts per million (ppm) refers to data per million by weight.

[0044] Unless otherwise specified, the measurements listed below were determined at a temperature of 25°C and a pressure of 1013 mbar.

[0045] In relation to this invention, "pH" is defined, unless otherwise specified, as the value measured for the relevant composition at 25°C after stirring for 5 minutes using a pH electrode calibrated in accordance with ISO 4316 (1977).

[0046] The bio-based surfactant contained in the composition according to the present invention is preferably an isolated bio-based surfactant.

[0047] In the context of this invention, the term "biological surfactant" refers to glycolipids produced by fermentation, and therefore the term "isolated biological surfactant" has the meaning commonly used in the field of biotechnology.

[0048] The compositions according to the present invention preferably include, as component A), at least one bio-surfactant selected from rhamnolipid, sophorolipid, glucolipid, cellulose lipid, mannosylerythritol lipid and trehalose lipid, preferably rhamnolipid, sophorolipid and glucolipid, preferably rhamnolipid and glucolipid, and most preferably rhamnolipid. Examples of bio-surfactants include European Patent No. 0499434, U.S. Patent No. 7,985,722, International Publication No. 03 / 006146, German Patent No. 19648439, German Patent No. 19600743, Japanese Patent Publication No. 01304034, Chinese Patent No. 1337439, Japanese Patent Publication No. 2006274233, Japanese Patent Publication No. 2006083238, and Japanese Patent Publication No. 200607023. It can be manufactured as described in Japanese Patent Publication No. 1, International Publication No. 03 / 002700, French Patent No. 2740779, German Patent No. 2939519, U.S. Patent No. 7,556,654, French Patent No. 2855752, European Patent No. 1445302, Japanese Patent Publication No. 2008062179 and Japanese Patent Publication No. 2007181789, or the documents cited therein. Suitable bio-based surfactants can be obtained, for example, from Soliance in France.

[0049] Preferably, the composition according to the present invention contains, as a bio-based surfactant, at least one selected from rhamnolipid, particularly monorhamnolipid, dirhamnolipid, or polyrhamnolipid, glucolipid, particularly monoglucolipid, diglucolipid, or polyglucolipid, and sophorolipid, particularly monosophorolipid, disophorolipid, or polysosophorolipid, preferably at least one selected from rhamnolipid and glucolipid, most preferably rhamnolipid.

[0050] In the context of the present invention, the term "rhamnolipide" preferably means, in particular, general formula (I) [ka] It is understood to mean the compounds and salts thereof. Here, mRL = 2, 1, or 0. nRL=1 or 0, R 1RL and R 2RL =Identical or distinct organic residues having 2 to 24, preferably 5 to 13, carbon atoms independently of each other, particularly optionally branched, optionally substituted, particularly hydroxysubstituted, optionally unsaturated, particularly optionally monovalent, divalent or trivalent unsaturated alkyl residues, preferably pentenyl, heptenyl, nonenyl, undecenyl and tridecenyl, and (CH2) o -Selected from the group consisting of CH3 [wherein o = 1 to 23, preferably 4 to 12].

[0051] When nRL=1, the glycosidic bond between the two rhamnose units is preferably in the α configuration. The optically active carbon atom of the fatty acid is preferably present as the R-enantiomer (e.g., (R)-3-{(R)-3-[2-O-(α-L-rhamnopyranosyl)-α-L-rhamnopyranosyl]oxydecanoyl}oxydecanoate).

[0052] In the context of this invention, the term "diramnolipide" is understood to mean a compound of general formula (I) or a salt thereof, where nRL=1.

[0053] In the context of the present invention, the term "monorhamnolipid" is understood to mean a compound of general formula (I) with nRL = 0 or a salt thereof.

[0054] Rhamnolipids of different types are abbreviated according to the following nomenclature: "diRL-CXCY" means a dirhamnolipid of general formula (I) where nRL = 1 and one of the residues R 1RL and R 2RL is (CH2) o -CH3 [where o = X - 4], and the remaining residue R 1RL or R 2RL is (CH2) o -CH3 [where o = Y - 4].

[0055] "monoRL-CXCY" means a monorhamnolipid of general formula (I) where one of R 1RL and R 2RL is (CH2) o -CH3 [where o = X - 4], and the remaining residue R 1RL or R 2RL is (CH2) o -CH3 [where o = Y - 4].

[0056] Thus, in the nomenclature used, "CXCY" and "CYCX" are not distinguished.

[0057] For rhamnolipids with mRL = 0, monoRL-CX or diRL-CX is used as appropriate.

[0058] When one of the above subscripts X and / or Y has ":Z" attached, this indicates that each of the residues R 1RL and / or R 2RL is equal to an unbranched and unsubstituted hydrocarbon residue having X - 3 or Y - 3 carbon atoms and having Z double bonds.

[0059] Methods for preparing the relevant rhamnolipide are disclosed, for example, in European Patent No. 2786743 and European Patent No. 2787065.

[0060] Rhamnolipide applicable in the context of the present invention can also be produced by fermentation of Pseudomonas, particularly Pseudomonas aeruginosa, preferably non-genetically modified cells, which is a technique already disclosed in the 1980s, as described, for example, in European Patent No. 0282942 and German Patent No. 4127908. Rhamnolipide produced in Pseudomonas aeruginosa cells improved by genetic recombination for higher rhamnolipide titers can also be used in the context of the present invention. Such cells are disclosed, for example, by Lei et al. in Biotechnol Lett. 2020 Jun;42(6):997-1002.

[0061] Rhamnolipid produced by Pseudomonas aeruginosa is marketed by Jeneil Biotech Inc. under the trade name Zonix, by Logos Technologies (technology acquired by Stepan) under the trade name NatSurFact, by Biotensidion GmbH under the trade name Rhapynal, by AGAE technologies under the names R90, R95, R95Md, and R95Dd, and by Locus Bio-Energy Solutions and Shanghai Yusheng Industry Co. Ltd. under the trade name Bio-201 Glycolipids.

[0062] The present invention provides a composition preferably comprising rhamnolipide as a bio-based surfactant, wherein component A), which is a bio-based surfactant, comprises 51% to 100% by weight, preferably 60% to 95% by weight, and particularly preferably 80% to 90% by weight of monorhamnolipide, in particular monorhamnolipide of formula (I) where nRL=0, and the weight percentage is relative to the total of all present rhamnolipides.

[0063] Surprisingly, this increases the viscosity of the composition according to the present invention. Preferably, this preferred embodiment is combined with an antifouling agent in a certain content (see below), preferably a carboxymethyl inulin type antifouling agent.

[0064] The present invention further provides a composition preferably comprising rhamnolipid as a bio-based surfactant, wherein component A), which is a bio-based surfactant, comprises 51% to 95% by weight, preferably 55% to 80% by weight, and particularly preferably 60% to 70% by weight of diRL-C10C10, and the weight percentage is relative to the total of all present rhamnolipids.

[0065] A preferred composition according to the present invention is characterized in that the composition contains the above-mentioned rhamnolipid as a bio-based surfactant in a diRL-C10C12:1 content of 0.5% to 15% by weight, preferably 3% to 12% by weight, and particularly preferably 5% to 10% by weight, where the weight percentage is relative to the total amount of all present rhamnolipids.

[0066] A further preferred composition according to the present invention is characterized in that the composition contains the above-mentioned rhamnolipid as a bio-based surfactant in a content of 0.5 to 25% by weight, preferably 3% to 15% by weight, and particularly preferably 5% to 12% by weight of diRL-C10C12, wherein the weight percentage is relative to the total amount of all rhamnolipids present.

[0067] A further preferred composition according to the present invention is characterized in that the composition contains the above-mentioned rhamnolipid as a bio-based surfactant in an amount of 0.1% to 25% by weight, preferably 2% to 10% by weight, and particularly preferably 4% to 8% by weight of diRL-C8C10, wherein the weight percentage is relative to the total amount of all rhamnolipids present.

[0068] A further preferred composition according to the present invention is characterized in that the composition contains the above-mentioned rhamnolipids as a bio-based surfactant in an amount of 0.1% to 5% by weight, preferably 0.5% to 3% by weight, particularly preferably 0.5% to 2% by weight of monoRL-C8C10, and / or preferably 0.1% to 5% by weight, preferably 0.5% to 3% by weight, particularly preferably 0.5% to 2% by weight of monoRL-C10C10, wherein the weight percentage is relative to the total amount of all present rhamnolipids.

[0069] The present invention provides a composition comprising, alternatively preferably, rhamnolipid as a bio-based surfactant, wherein component A), which is a bio-based surfactant, comprises 10% to 50% by weight, preferably 20% to 40% by weight, and particularly preferably 25% to 35% by weight of monoRL-C10C10, and the weight percentage is relative to the total of all present rhamnolipids.

[0070] An alternatively preferred composition according to the present invention is characterized in that the composition contains the above-mentioned rhamnolipid as a bio-based surfactant in an amount of 10% to 30% by weight, preferably 12% to 25% by weight, and particularly preferably 15% to 20% by weight of diRL-C10C10, where the weight percentage is relative to the total amount of all present rhamnolipids.

[0071] An alternatively preferred composition according to the present invention is characterized in that the composition contains the above-mentioned rhamnolipid as a bio-based surfactant in an amount of 10% to 30% by weight, preferably 12% to 25% by weight, and particularly preferably 15% to 20% by weight of monoRL-C8C10, where the weight percentage is relative to the total amount of all present rhamnolipids.

[0072] An alternatively preferred composition according to the present invention is characterized in that the composition contains the above-mentioned rhamnolipid as a bio-based surfactant in a monoRL-C10C12:1 content of 3% to 25% by weight, preferably 5% to 20% by weight, and particularly preferably 10% to 15% by weight, where the weight percentage is relative to the total amount of all present rhamnolipids.

[0073] An alternatively preferred composition according to the present invention is characterized in that the composition contains the above-mentioned rhamnolipid as a bio-based surfactant in a diRL-C10C12 content of 1% to 15% by weight, preferably 2% to 10% by weight, and particularly preferably 3% to 8% by weight, where the weight percentage is relative to the total of all present rhamnolipids.

[0074] In the context of the present invention, the term "sophorolipide" is preferably of general formulas (IIa) and (IIb) [ka] It is understood to mean the compounds of and their salts. Here, R 1SL =H or CO-CH3, R 2SL =H or CO-CH3, R 3SL = A divalent organic moiety containing 6 to 32 carbon atoms, either unsubstituted or substituted by a hydroxyl functional group, unbranched, and optionally containing 1 to 3 double or triple bonds. R 4SL=H, CH3, or a monovalent organic radical containing 2 to 10 carbon atoms, unsubstituted or substituted with a hydroxyl functional group, unbranched, and optionally containing 1 to 3 double or triple bonds. nSL = 1 or 0.

[0075] Sophorolipide can be used in its acidic or lactone form according to the present invention.

[0076] A preferred composition according to the present invention comprises a sophorolipid having a weight ratio of lactone form to acid form in the range of 20:80 to 80:20, particularly preferably in the range of 30:70 to 40:60.

[0077] To determine the content of sophorolipid in acid or lactone form in the formulation, refer to paragraph

[0053] on page 8 of European Patent No. 1411111.

[0078] In relation to the present invention, the term "glucoripide" is preferably of general formula (III) [ka] It is understood to mean the compounds and salts thereof. Here, mGL = 3, 2, 1, or 0, preferably 1 or 0. R 1GL and R 2GL =Identical or distinct organic radicals having 2 to 24 carbon atoms independently of each other, particularly optionally branched, optionally substituted, particularly hydroxysubstituted, optionally unsaturated, particularly optionally monovalent, divalent or trivalent unsaturated alkyl radicals, preferably pentenyl, heptenyl, nonenyl, undecenyl and tridecenyl, and (CH2) o -Selected from the group consisting of CH3 [wherein o = 1 to 23, preferably 4 to 12].

[0079] Different types of glucolipide are abbreviated according to the following nomenclature: "GL-CXCY" is a radical R 1GL and R 2GL One of them is (CH2) o -CH3 [where o = X - 4], and the remaining radical R 1GL or R 2GL (CH2) o It is understood to mean the glucolipide of general formula (III) -CH3 [where o = Y-4].

[0080] Therefore, in the nomenclature used, "CXCY" and "CYCX" are not distinguished.

[0081] If either of the above subscripts X and / or Y is followed by ":Z", this refers to the respective radical R 1GL and / or R 2GL However, this indicates that it is an unbranched, unsubstituted hydrocarbon radical having X-3 or Y-3 carbon atoms and possessing Z double bonds.

[0082] The method for producing glucolipide can be carried out as described in International Publication No. 2019154970.

[0083] In the context of the present invention, when determining the content of component A), the mass of the non-salt form is considered, and therefore the weight of the corresponding cation is ignored.

[0084] In the context of the present invention, the content of component B) refers, for example, to manganese ions in solution, rather than solid manganese salts in the composition.

[0085] To determine the manganese ion content in the composition according to the present invention, inductively coupled plasma mass spectrometry (ICP-MS) methodology is preferably used.

[0086] The composition according to the present invention may contain high concentrations of components A) and B), and is advantageously useful, for example, in the production of formulations for end customers.

[0087] In this context, the present invention preferably describes a composition according to the present invention. A) At least one biological surfactant in an amount of 25% to 75% by weight, more preferably 40% to 70% by weight, B) Manganese ions in a concentration of 0.1 ppm to 500 ppm, more preferably 0.5 ppm to 50 ppm, and even more preferably 1.0 ppm to 19 ppm. Includes, The weight percentages and parts per million are characterized by being relative to the entire composition.

[0088] The composition according to the present invention can have concentrations of components that are advantageously useful as a final product for end customers.

[0089] In this context, the present invention preferentially provides a composition according to the present invention. A) At least one bio-based surfactant in an amount of 0.5% to 25% by weight, more preferably 1.0% to 20% by weight, and most preferably 3.0% to 15% by weight, B) Manganese ions in a concentration of 0.01 ppm to 500 ppm, more preferably 0.5 ppm to 50 ppm, and even more preferably 1.0 ppm to 19 ppm. Includes, The weight percentages and parts per million are characterized by being relative to the entire composition.

[0090] The alternatively preferred compositions according to the present invention are preferably pharmaceutical formulations, particularly dermatological formulations or cosmetic formulations.

[0091] These alternatively preferred compositions according to the present invention are, alternatively, preferably household care formulations, such as cleaning formulations or laundry formulations.

[0092] The composition according to the present invention preferably contains water in an amount of 5% to 95% by weight, more preferably 20% to 80% by weight, and more preferably 30% to 70% by weight, where the weight percentage is relative to the whole composition.

[0093] The composition according to the present invention preferably has a pH of 2.0 to 12.5, preferably 5.0 to 10.0, and particularly preferably 5.5 to 9.0.

[0094] When the composition according to the present invention is used, for example, in a laundry detergent, it preferably has a pH of 7.0 to 12.5, more preferably 7.5 to 12.0, and particularly preferably 8.0 to 12.0.

[0095] When the composition according to the present invention is used, for example, in a hand-washing dish soap or cosmetic, it preferably has a pH of 4 to 8, more preferably 4.5 to 7.5, and particularly preferably 5 to 6.5.

[0096] The compositions according to the present invention preferably have a Gardner color value in the range of 0.01 to 15, preferably 0.5 to 8, and more preferably 1 to 5.

[0097] The composition according to the present invention is preferably, C) At least one type of preservative Includes.

[0098] The composition according to the present invention preferably contains the above-mentioned preservative, p-Anisic acid, benzoic acid, levulinic acid, sorbic acid, lactic acid, mandelic acid, salicylic acid, dehydroacetic acid, caprylhydroxamic acid, cinnamic acid, geranic acid, pelargonic acid, and salts of the aforementioned acids. Methylparaben, ethylparaben, Phenylpropanol, benzyl alcohol, phenethyl alcohol, phenoxyethanol, Propanediol, pentylene glycol, 1,2-hexanediol, caprylyl glycol, undecyl alcohol, methylpropanediol, Ethylhexylglycerin, n-octylglycerin, n-heptylglycerin, n-hexylglycerin, methylheptylglycerin, Undecylenamidopropyltrimonium methosulfate, Isothiazolinone, preferably an isothiazolinone selected from chloromethylisothiazolinone (CIT), methylisothiazolinone (MIT), benzisothiazolinone (BIT), and butylbenzisothiazolinone (BBIT), Triethyl citrate, Citral, Hydroxymethylglycinate, glyceryl caprylate, Propynyl iodide butylcarbamate (IPBC), and Sodium caproyl / lauroyl lactate The group is characterized by being selected from a group that includes, preferably a group consisting of, these.

[0099] The composition according to the present invention can be formulated as a cosmetic composition, preferably in which case the following applies: The composition according to the present invention is preferably, Cosmetic active ingredients, Skin softener, emulsifier, Thickening agent / viscosity modifier / stabilizer, UV light protection filter, Antioxidants, Hydrotrope, Solids and fillers, Film-forming agent, Pearlescent luster additive, Deodorizing and antiperspirant active ingredients, Insect repellent, Self-tanning products, Conditioning agent, fragrance, dye, Odor absorber, Superfat agent, Other solvents, Preferably, it is a cosmetic active ingredient. It includes at least one additional component selected from the group.

[0100] Substances that can be used as exemplary representative examples of individual groups are known to those skilled in the art and can be found, for example, in German Patent Application No. 102008001788.4, which is incorporated herein by reference and thus forms part of this disclosure.

[0101] For further optional components and the amounts of these components used, the relevant handbook known to those skilled in the art is explicitly referenced, for example, K. Schrader, “Grundlagen und Rezepturen der Kosmetika [Cosmetics - fundamentals and formulations]”, 2nd edition, pages 329 to 341, Huethig Buch Verlag Heidelberg.

[0102] The amount of a particular additive depends on its intended use.

[0103] Typical boundary formulations for each application are known prior art and are included, for example, in the brochures of manufacturers of specific bases and active ingredients. These existing formulations can generally be adopted without modification. However, if necessary, desired modifications can be made by simple testing without complexity for adjustment and optimization.

[0104] The composition according to the present invention can be formulated as a home care composition, preferably in which case the following applies: The compositions according to the present invention preferably include bleaching agents, hydrotropes, polymers which may be synthetic polymers, biopolymers, anti-redeposition aids, fiber protectants, antifouling agents, anti-color transfer agents, fabric hueing agents, opaque agents, blue dyes, enzyme stabilizers, solvents, viscosity modifiers, preservatives, pH adjusters, and one or more auxiliary agents selected from the group consisting of salts such as NaCl and Na2SO4.

[0105] A further aspect of the present invention is a method for stabilizing the color of a composition containing a biological surfactant, a) A step of preparing a composition containing a biological surfactant, b) A step of adding manganese to the composition to a manganese ion concentration of 0.01 ppm to 500 ppm, preferably 0.10 ppm to 200 ppm, more preferably 1.0 ppm to 50 ppm, and most preferably 2.0 ppm to 19 ppm, wherein the parts per million is relative to the entire composition. This method includes [something].

[0106] A preferred method according to the present invention is characterized in that manganese is added in the form of manganese oxide, manganese hydroxide and / or manganese salt, preferably as an aqueous solution, wherein the oxide is preferably selected from the group MnO2, Mn3O4, Mn2O3, MnO, Mn2O7 and MnO3, and the salt is preferably selected from the group MnSO4, MnCl2, Mn(CH3CO2)2, MnCO3, Mn(NO3)2, manganese gluconate and manganese permanganate, for example KMnO4.

[0107] Preferably, the bio-based surfactant included in the composition prepared in step a) of the method of the present invention is an isolated bio-based surfactant.

[0108] A preferred method according to the present invention is characterized in that the above-mentioned biological surfactant is selected from the group consisting of rhamnolipide, glucolipide, and sophorolipide, preferably rhamnolipide and glucolipide, and most preferably rhamnolipide.

[0109] A preferred method according to the present invention is characterized in that the composition containing the bio-based surfactant prepared in step a) has a Gardner color value in the range of 0.01 to 15, preferably 0.5 to 8, and more preferably 1 to 5.

[0110] The most suitable methodology for determining Gardner color values ​​is the third edition of ISO 4630-2015 Clear liquids - Estimation of color by the Gardner color scale.

[0111] For example, in the case of turbid substances such as emulsions, a different methodology is needed to determine the color.

[0112] The CIELAB color space is L * a * It is defined by the b value, and lightness L is the color-related index.

[0113] A preferred method according to the present invention is characterized in that the composition containing the bio-based surfactant prepared in step a) has an L color value in the CIELAB color space in the range of 20 to 100, preferably 30 to 95, and more preferably 50 to 90.

[0114] A suitable methodology for determining the L color value in the CIELAB color space is the measurement of surface reflection using Konica Minolta's CM-700d spectrophotometer.

[0115] In the method according to the present invention, particularly preferred embodiments of the composition according to the present invention and their preferred components are equally preferred in terms of their quantities within the context of the method according to the present invention.

[0116] A further aspect of the present invention is the use of manganese ions to improve the color stability of a composition comprising at least one biological surfactant.

[0117] A further aspect of the present invention is the use of manganese ions to prevent malodors in compositions containing at least one biological surfactant.

[0118] In use according to the present invention, particularly preferred embodiments of the compositions and methods according to the present invention, as well as their preferred components, are equally preferred in terms of their quantities, within the context of use according to the present invention.

[0119] The embodiments described below illustrate the present invention as an example, and the scope of application of the present invention is not intended to be limited in any way to the embodiments specified in the embodiments, as is clear from the entirety of this specification and the claims. [Brief explanation of the drawing]

[0120] [Figure 1] This figure shows the dose-dependent color stabilization of 50% rhamnolipid by MnSO4. [Figure 2] This figure shows the dose-dependent color stabilization of 15% rhamnolipid by MnSO4. [Figure 3] This figure shows the dose-dependent color stabilization of 15% rhamnolipid by manganese oxide. [Figure 4] This figure shows the dose-dependent color instability of 15% rhamnolipid by iron and copper ions. [Figure 5] This figure shows the dose-dependent color stabilization of 50% glucolipid by MnSO4.

[0121] Examples: Example 1: Dose-dependent color stabilization of a 50% rhamnolipid solution with MnSO4. Rhamnolipide was prepared as described in Example 1 of European Patent No. 3023431.

[0122] MnSO4×H2O was pre-diluted to 1 ppm and 100 ppm Mn from a 1% (w / w) pre-dilution with water. 2+ The solution was added to a 50% by weight rhamnolipid aqueous solution until it reached its final concentration, and then thoroughly mixed.

[0123] The samples were placed in airtight containers and incubated at 45°C.

[0124] Samples were collected at the specified time and measured spectrophotometrically in accordance with ISO 4630.

[0125] The results (Gardner) are shown in Figure 1.

[0126] Example 2: Dose-dependent color stabilization of a 15% rhamnolipid solution with MnSO4 Rhamnolipide was prepared as described in Example 1 of European Patent No. 3023431.

[0127] MnSO4×H2O was pre-diluted to 1 ppm and 100 ppm Mn from a 1% (w / w) pre-dilution with water. 2+ The solution was added to a 15% by weight rhamnolipid aqueous solution until it reached its final concentration, and then thoroughly mixed.

[0128] The samples were placed in airtight containers and incubated at 45°C.

[0129] Samples were collected at the specified time and measured spectrophotometrically in accordance with ISO 4630.

[0130] The results (Gardner) are shown in Figure 2.

[0131] Example 3: Color stabilization of 15% rhamnolipid solution with various manganese oxides Rhamnolipide was prepared as described in Example 1 of European Patent No. 3023431.

[0132] Manganese oxide was added to 15 wt% rhamnolipid aqueous solution at concentrations of 500 and 3000 ppm and incubated at room temperature for 60 minutes with stirring. Subsequently, the manganese oxide was separated by filtration using a pressure strainer (1 bar) equipped with a K800 filter disc (Seitz PALL).

[0133] As a result, low concentrations (<10 ppm) of Mn 2+ A composition containing the above is obtained.

[0134] The samples were placed in airtight containers and incubated at 45°C.

[0135] Samples were collected at the specified time and measured spectrophotometrically in accordance with ISO 4630.

[0136] The results (Gardner) are shown in the table and Figure 3 below.

[0137] [Table 1]

[0138] Example 4 (not according to the present invention): Dose-dependent color effect of iron and copper salts on a 15% rhamnolipid solution. Rhamnolipide was prepared as described in Example 1 of European Patent No. 3023431.

[0139] FeSO4×7H2O or CuSO4×5H2O was added to the diram nolipid material from a 1% (w / w) pre-dilution to the final concentration and thoroughly mixed. The samples were packed into airtight containers and incubated at 45°C. Samples were taken at the specified time points and measured spectrophotometrically in accordance with ISO 4630.

[0140] The results (Gardner) are shown in Figure 4.

[0141] Example 5: Dose-dependent color stabilization of a 50% glucolipid solution with MnSO4 Glucolipide was prepared as described in International Publication No. 2019 / 154970.

[0142] MnSO4×H2O was pre-diluted with water to 10 ppm and 25 ppm Mn 2+ The solution was added to a 50% by weight aqueous glucolipid solution until it reached its final concentration, and then thoroughly mixed.

[0143] The samples were placed in airtight containers and incubated at 45°C.

[0144] Samples were collected at the specified time and measured spectrophotometrically in accordance with ISO 4630.

[0145] The results (Gardner) are shown in Figure 5.

[0146] Example 6: Use of MnSO4 to prevent malodor in a bio-based surfactant composition Rhamnolipide was prepared as described in Example 1 of European Patent No. 3023431.

[0147] MnSO4×H2O was pre-diluted with water at a 1% (w / w) concentration, resulting in 0 ppm and 10 ppm Mn 2+ The solution was added to a 50% by weight rhamnolipid aqueous solution until it reached its final concentration, and then thoroughly mixed.

[0148] Next, the samples were placed in airtight containers and incubated at 45°C for 50 days.

[0149] The effect of manganese on the functional properties of rhamnolipide compositions was tested by odor evaluation using a panel of trained panelists.

[0150] In this context, "trained panelists" refers to individuals who have been pre-screened for their olfactory sensitivity and have experience comparing biological surfactant samples. Furthermore, the panelists were familiar with the malodorous samples before evaluating them.

[0151] The results are shown in the table below, using a scale of 1 to 5 for the odor characteristic "rancid odor".

[0152] [Table 2]

[0153] Example 7: Formulation Example Rhamnolipid (RL) was prepared as described in Example 1 of European Patent No. 3023431.

[0154] Monoramnolipide (mRL) was prepared as described in Example 2 of European Patent No. 3672690.

[0155] The sophorolipid (SL) used was Evonik's sophorolipid REWOFERM® SL ONE, with a lactone-to-acid ratio of 40:60.

[0156] Glucolipid (GL) was produced by fermentation according to Example 2 of International Publication No. 2019154970.

[0157] MnSO4×H2O was used as the manganese source.

[0158] The following compositions were prepared in water: [Table 3]

[0159] The following formulations are prepared using each of the stock solutions SF1 to SF10, where SFX represents the respective stock solution. Therefore, ten different formulations are explicitly disclosed in each of the following formulation tables.

[0160] [Table 4]

[0161] [Table 5]

[0162] [Table 6]

[0163] [Table 7]

[0164] Table 8

[0165] Table 9

[0166] Table 10

[0167] Table 11

[0168] Table 12

[0169] Table 13

[0170] Table 14

[0171] Table 15

[0172] Table 16

[0173] Table 17

[0174] Table 18

[0175] Table 19

[0176] Table 20

[0177] Table 21

[0178] Table 22

[0179] Table 23

[0180] Table 24

[0181] Table 25

[0182] Table 26

[0183] Table 27

[0184] Table 28

[0185] Table 29

[0186] Table 30

[0187] Table 31

[0188] Table 32

[0189] Table 33

[0190] Table 34

[0191] Table 35

[0192] Table 36

[0193] Table 37

[0194] Table 38

[0195] Table 39

[0196] Table 40

[0197] Table 41

[0198] Table 42

[0199] Table 43

[0200] Table 44

[0201] Table 45

[0202] Table 46

[0203] Table 47

[0204] Table 48

[0205] Table 49

[0206] Table 50

[0207] Table 51

[0208] Table 52

[0209] Table 53

[0210] Table 54

[0211] Table 55

[0212] Table 56

[0213] Table 57

[0214] Table 58

[0215] Table 59

[0216] Table 60

[0217] Table 61

[0218] Table 62

[0219] Table 63

[0220] Table 64

[0221] Table 65

[0222] Table 66

[0223] Table 67

[0224] Table 68

[0225] Table 69

[0226] Table 70

[0227] Table 71

[0228] Table 72

[0229] Table 73

[0230] Table 74

[0231] Table 75

[0232] Table 76

[0233] Table 77

[0234] Table 78

[0235] Table 79

[0236] Table 80-1 Table 80-2

[0237] [Table 81]

[0238] [Table 82]

[0239] [Table 83]

[0240] [Table 84]

[0241] Shampoo ingredient list: [Table 85]

[0242] [Table 86]

[0243] [Table 87]

[0244] [Table 88]

[0245] [Table 89]

[0246] [Table 90]

[0247] Table 91

[0248] Table 92

[0249] Table 93

[0250] Table 94-1 Table 94-2

[0251] Table 95

[0252] Table 96

[0253] Table 97

[0254] Table 98

[0255] Table 99

[0256] Table 100

[0257] Table 101

[0258] Table 102

[0259] Table 103

[0260] Table 104

[0261] Table 105

[0262] Table 106

[0263] Table 107

[0264] Table 108

[0265] Table 109

[0266] Table 110

[0267] Table 111

[0268] Table 112

[0269] Table 113

[0270] Table 114

[0271] Table 115

[0272] Table 116

[0273] Table 117

[0274] Table 118

[0275] Table 119

[0276] Table 120

[0277] Table 121-1 Table 121-2

[0278] Table 122

[0279]

Table 123

[0280] Table 124

[0281] Table 125

[0282] Table 126

[0283] Table 127

[0284] Table 128

[0285] Table 129

[0286] Table 130

[0287] Table 131

[0288] Table 132

[0289] Table 133

[0290] Table 134

[0291] Table 135

[0292] Table 136

[0293] Table 137

[0294] Table 138

[0295] Table 139

[0296] Table 140

[0297] [Table 141]

[0298] [Table 142]

[0299] Shower Mixing Chart [Table 143]

[0300] [Table 144]

[0301] [Table 145]

[0302] [Table 146]

[0303] [Table 147]

[0304] [Table 148]

[0305] [Table 149]

[0306] [Table 150]

[0307] Table 151

[0308] Table 152

[0309] Table 153

[0310] Table 154

[0311] Table 155

[0312] Table 156

[0313] Table 157

[0314] Table 158

[0315] Table 159

[0316] Table 160

[0317] Table 161

[0318] Table 162

[0319] Table 163

[0320] Table 164

[0321] Table 165

[0322] Table 166

[0323] Table 167

[0324] Table 168

[0325] Stonebird combination table Table 169

[0326] Table 170

[0327] Table 171

[0328] Table 172

[0329] Table 173

[0330] Table 174

[0331] Table 175

[0332] Table 176

[0333] Table 177

[0334] Table 178

[0335] Table 179

[0336] Table 180

[0337] Table 181

[0338] Bathing agent matching list Table 182

[0339] Table 183

[0340] Table 184

[0341] Table 185

[0342] Table 186

[0343] Table 187

[0344] Table 188

[0345] Table 189

[0346] Table 190

[0347] xイン1 coordination table Table 191

[0348] Table 192

[0349] Table 193

[0350] Table 194

[0351] Table 195

[0352] Table 196

[0353] Table 197

[0354] Table 198

[0355] Washing paint matching table Table 199

[0356] Table 200

[0357] Table 201

[0358] Table 202

[0359] Table 203

[0360] Table 204

[0361] Table 205

[0362] Table 206

[0363] Table 207

[0364] Table 208

[0365] Table 209

[0366] Table 210

[0367] Table 211

[0368] Table 212

[0369] Table 213

[0370] Table 214

[0371] Table 215

[0372] Table 216

[0373] Table 217

[0374] Table 218

[0375] Table 219

[0376] Table 220

[0377] Table 221

[0378] [Table 222]

[0379] [Table 223]

[0380] [Table 224]

[0381] [Table 225]

[0382] [Table 226]

[0383] Microemulsion Formulation Chart [Table 227]

[0384] [Table 228]

[0385] Toothpaste ingredient list [Table 229]

[0386] [Table 230]

[0387] [Table 231]

[0388] Table 232

[0389] Table 233

[0390] Table 234

[0391] Table 235

[0392] Table 236

[0393] Table 237

[0394] Table 238

[0395] Table 239

[0396] Table 240

[0397] Table 241

[0398] Table 242

[0399] Table 243

[0400] Table 244

[0401] Table 245

[0402] Table 246

[0403] Table 247

[0404] Table 248

[0405] Table 249

[0406] Table 250

[0407] Table 251

[0408] Table 252

[0409] Table 253

[0410] Table 254

[0411] Table 255

[0412] Table 256

[0413] Table 257

[0414] Table 258

[0415] Table 259

[0416] Table 260

[0417] Table 261

[0418] Table 262

[0419] [Table 263]

[0420] [Table 264]

[0421] [Table 265]

[0422] Mouthwash ingredient list [Table 266]

[0423] [Table 267]

[0424] [Table 268]

[0425] [Table 269]

[0426] [Table 270]

[0427] [Table 271]

[0428] [Table 272]

[0429] Table 273

[0430] Table 274

[0431] Table 275

[0432] Table 276

[0433] Table 277

[0434] Table 278

[0435] Table 279

[0436] Table 280

[0437] Table 281

[0438] Table 282

[0439] Table 283

[0440] Table 284

[0441] Table 285

[0442] Table 286

[0443] Table 287

[0444] Table 288

[0445] Table 289

[0446] Table 290

[0447] Table 291

[0448] Table 292

[0449] Table 293

[0450] Table 294

[0451] Table 295

[0452] Table 296

[0453] Table 297

[0454] Table 298

[0455] Table 299

[0456] Table 300

[0457] Table 301

[0458] Table 302

[0459] Table 303

[0460] [Table 304]

[0461] [Table 305]

[0462] Further formulation (weight %) [Table 306-1] [Table 306-2]

[0463] [Table 307-1] [Table 307-2]

[0464] [Table 308-1] [Table 308-2]

[0465] [Table 309-1] [Table 309-2]

[0466] [Table 310]

[0467] Table 311

[0468] Table 312

[0469] Table 313

[0470] Table 314

[0471] Table 315

[0472] Table 316

[0473] Table 317

[0474] Table 318

[0475] Table 319

[0476] Table 320

[0477] Table 321

[0478] Table 322

[0479] Table 323

[0480] Table 324

[0481] Table 325

[0482] Table 326

[0483] Table 327

[0484] Table 328

[0485] Table 329

[0486] Table 330

[0487] Table 331

[0488] Table 332

[0489] Table 333

[0490] Table 334

[0491] Table 335

[0492] Table 336

[0493] Table 337

[0494] Table 338

[0495] Table 339

[0496] Table 340

[0497] Table 341

[0498] Table 342

[0499] Table 343

[0500] Table 344

[0501] Table 345

[0502] Table 346

[0503] Table 347

[0504] Table 348

[0505] Table 349

[0506] Table 350

[0507] Table 351

[0508] Table 352

[0509] Table 353

[0510] Table 354

[0511] Table 355

[0512] Table 356

[0513] Table 357

[0514] Table 358

[0515] Table 359

[0516]

Table 360

[0517] Table 361

[0518] Table 362

[0519] Table 363

[0520] Table 364

[0521] Table 365

[0522] Table 366

[0523] Table 367

[0524] Table 368

[0525] Table 369

[0526] Table 370

[0527] Table 371

[0528] Table 372

[0529] Table 373

[0530] Table 374

[0531] Table 375

[0532] Table 376

[0533] Table 377

[0534] Table 378

[0535] Table 379

[0536] Table 380

[0537] Table 381

[0538] Table 382

[0539] Table 383

[0540] Table 384

[0541] Table 385

[0542] Table 386

Claims

1. A) At least one biological surfactant in an amount of 0.5% to 90% by weight, preferably 3.0% to 85% by weight, more preferably 15% to 80% by weight, more preferably 25% to 75% by weight, and most preferably 40% to 70% by weight, B) Manganese ions in a concentration of 0.01 ppm to 500 ppm, preferably 0.1 ppm to 200 ppm, more preferably 1.0 ppm to 50 ppm, and most preferably 2.0 ppm to 19 ppm. A composition comprising, A composition in which the weight percentage and parts per million are relative to the whole composition.

2. A) At least one biological surfactant in an amount of 25% to 75% by weight, more preferably 40% to 70% by weight, B) Manganese ions in a concentration of 0.1 ppm to 500 ppm, more preferably 0.5 ppm to 50 ppm, and even more preferably 1.0 ppm to 19 ppm. Includes, The composition according to claim 1, characterized in that the weight percentage and parts per million are relative to the entire composition.

3. A) At least one biological surfactant in an amount of 0.5% to 25% by weight, more preferably 1.0% to 20% by weight, and most preferably 3.0% to 15% by weight, B) Manganese ions in a concentration of 0.01 ppm to 500 ppm, more preferably 0.5 ppm to 50 ppm, and even more preferably 1.0 ppm to 19 ppm. Includes, The composition according to claim 1, characterized in that the weight percentage and parts per million are relative to the entire composition.

4. The composition according to any one of claims 1 to 3, characterized in that the biological surfactant is selected from the group consisting of rhamnolipide, glucolipide, and sophorolipide, preferably rhamnolipide and glucolipide, and most preferably rhamnolipide.

5. C) At least one type of preservative A composition according to any one of claims 1 to 4, characterized by containing the following:

6. The aforementioned preservative is p-Anisic acid, benzoic acid, levulinic acid, sorbic acid, lactic acid, mandelic acid, salicylic acid, dehydroacetic acid, caprylhydroxamic acid, cinnamic acid, geranic acid, pelargonic acid, and salts of the aforementioned acids, Methylparaben, ethylparaben, Phenylpropanol, benzyl alcohol, phenethyl alcohol, phenoxyethanol, Propanediol, pentylene glycol, 1,2-hexanediol, caprylyl glycol, undecyl alcohol, methylpropanediol, Ethylhexylglycerin, n-octylglycerin, n-heptylglycerin, n-hexylglycerin, methylheptylglycerin, Undecylenamidopropyltrimonium methosulfate, Isothiazolinone, Triethyl citrate, Citral, Hydroxymethylglycinate, glyceryl caprylate, Iodide propynyl butylcarbamate, and Caproyl / Sodium Lauroyl Lactate The composition according to any one of claims 1 to 5, characterized in that it is selected from the group including, preferably from the group consisting of, the following.

7. A method for stabilizing the color of a composition containing a biological surfactant, a) A step of preparing a composition containing a biological surfactant, b) A step of adding manganese to the composition to a manganese ion concentration of 0.01 ppm to 500 ppm, preferably 0.10 ppm to 200 ppm, more preferably 1.0 ppm to 50 ppm, and most preferably 2.0 ppm to 19 ppm, wherein the parts per million is relative to the whole composition. Methods that include...

8. The manganese is added in the form of manganese oxide and / or manganese salt, preferably as an aqueous solution, and the oxide is preferably MnO ２ , Mn ３ O ４ , Mn ２ O ３ , MnO, Mn ２ O ７ and MnO ３ is selected from the group consisting of, and the salt is preferably MnSO ４ , MnCl ２ , Mn(CH ３ CO ２ ), ２ , MnCO ３ , Mn(NO ３ ), ２ and manganese gluconate, and the method according to claim 7, characterized in that it is selected from the group consisting of.

9. The method according to claim 7 or 8, characterized in that the biological surfactant is selected from the group consisting of rhamnolipide, glucolipide, and sophorolipide, preferably rhamnolipide and glucolipide, and most preferably rhamnolipide.

10. The method according to any one of claims 7 to 9, characterized in that the composition comprising the biological surfactant prepared in step a) has a Gardner color value in the range of 0.01 to 15, preferably 0.5 to 8, and more preferably 1 to 5.

11. The method according to any one of claims 7 to 10, characterized in that the composition containing the biological surfactant prepared in step a) has an L color value in the CIELAB color space in the range of 20 to 100, preferably 30 to 95, and more preferably 50 to 90.

12. Use of manganese ions to improve the color stability of a composition containing at least one biological surfactant.

13. The use of manganese ions to prevent malodors in compositions containing at least one type of biological surfactant.

Images